Skip to content

Effect of intratracheal dexmedetomidine combined with ropivacaine on postoperative sore throat: a prospective randomized, double-blinded, placebo-controlled trial

Effect of intratracheal dexmedetomidine combined with ropivacaine on postoperative sore throat: a prospective randomized, double-blinded, placebo-controlled trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900022907
Enrollment
Unknown
Registered
2019-04-30
Start date
2019-05-13
Completion date
Unknown
Last updated
2019-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thoracolumbar spinal operation

Interventions

Group D:intratracheal dexmedetomidine
Group R:intratracheal ropivacaine
Group DR:intratracheal dexmedetomidine combined with ropivacaine

Sponsors

The First People's Hospital of Hefei, Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients to be scheduled for elective thoracolumbar spinal operation under general anesthesia

Exclusion criteria

Exclusion criteria: Patients with a BMI 30 kg/m2, heart rate (HR) <50 bpm at a pre-operativevisit, renal or hepatic disease, opioids or tranquilizersiffic usage (treat for more than 1 wk before the operation), a history of alcohol or drug abuse, ASA physical status III or greater, contraindications to any of the drugs used in the study, and pregnancy. Moreover,difficult airway or history of maxillofacial and neck surgery; chronic respiratory disease such as chronic obstructive pulmonary disease or asthma, recent respiratory tract infection, chronic cough, current smoking, anesthesia time more than 4 h, and delayed extubation (more than 1 h without extubation) because of adverse effect to experimental drugs, transferd to the Intensive Care Unit (ICU) with the tube were eliminated.

Design outcomes

Primary

MeasureTime frame
Sore throat;

Secondary

MeasureTime frame
HR and MAP;analgesic drug consumption;First injection of Remifentanil;

Countries

China

Contacts

Public ContactYu Junma

The First People's Hospital of Hefei, Anhui Medical University

majuny163@163.com+86 15505510801

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026